@simonwfitness's cryptic MT2 claim, fact-checked

What did @simonwfitness actually say?

Honestly, not much, at least not out loud. The transcript is three seconds of "when you know you know" and a laugh. The real content is in the hashtags: #mt2 and #ghkcu. MT-2, also known as Melanotan II, is a synthetic peptide analogue of alpha-melanocyte-stimulating hormone. The "bee sting" caption is a wink at subcutaneous injection, the delivery method for MT-2. So what we have here is a vibe-post that implies firsthand peptide use without technically stating anything. Classic plausible-deniability content.

The joke lands with a specific audience: people who already know that MT-2 is injected and produces effects that range from tanning to libido changes. The creator isn't making a medical claim, but the implication is that personal experience has been positive enough to laugh about discomfort. That framing matters when we try to evaluate what viewers are actually being told.

Does the science back this up?

Melanotan II does what it's rumored to do, the evidence just isn't clean enough to call it validated therapy. The peptide binds to melanocortin receptors (MC1R through MC5R) and the research on its effects is real but messy.

On tanning: MC1R activation increases eumelanin production in melanocytes. Studies like Dorr et al. (1996, Archives of Dermatology) confirmed pigmentation increases in human subjects at low doses. That part is pharmacologically coherent.

On libido: PT-141 (bremelanotide), a close structural relative, was actually FDA-approved in 2019 for hypoactive sexual desire disorder in premenopausal women. That approval gives some indirect credibility to MT-2's mechanism. But MT-2 itself has not been approved and the dose-response curve in uncontrolled settings is genuinely unpredictable.

GHK-Cu, the second hashtag, is a copper tripeptide with better-studied wound healing and collagen synthesis data, including work by Pickart and Margolina (2018, Biomolecules). The science there is more consistent, though mostly in vitro or animal models.

What did they get wrong (or right)?

This is a hard one to grade because the creator technically said nothing verifiable. But the implied message, that MT-2 injection is a casual, laugh-worthy personal routine, skips over some genuinely important concerns.

What they got right: MT-2 does produce the effects the community attributes to it. The pharmacology is real. The "bee sting" framing is accurate to the injection experience.

What the framing misses:

• MT-2 is not FDA-approved for any indication. Compounded or gray-market versions have no standardized purity testing.
• Side effects include nausea, facial flushing, spontaneous erections, and blood pressure changes. Dorr et al. (1996) documented nausea in a significant portion of subjects even at controlled doses.
• There are unresolved concerns about MT-2 and existing nevi (moles). The peptide stimulates melanocytes broadly, not selectively. Dermatologists have flagged this as a reason for caution in people with atypical mole patterns.
• Sourcing is essentially unregulated. What someone orders from a research chemical supplier may not be what the label says.

The humor-and-implication format normalizes use without addressing any of this. That's not a neutral act when you have 244,000 people watching.

What should you actually know?

If you're curious about MT-2 or GHK-Cu after watching this video, here's what the evidence actually supports, without the vibe-posting.

Melanotan II is a pharmacologically active compound with measurable effects on pigmentation, sexual function, and appetite. It is not a cosmetic supplement. It acts on the central nervous system via melanocortin receptors, which is why side effects aren't just skin-deep. A 2003 review by King et al. in Peptides described the broad physiological reach of melanocortin signaling, including cardiovascular and neurological effects.

GHK-Cu is a different category entirely. It's a naturally occurring peptide in human plasma that declines with age. The topical and injectable research is more favorable and the safety profile looks considerably cleaner than MT-2. Still, most human trial data is limited in scale.

Neither compound should be self-administered based on TikTok content. If you're interested in peptide therapy, that conversation belongs with a licensed provider who can review your full health picture, including skin history, cardiovascular status, and any medications that interact with melanocortin pathways.

The "iykyk" framing works because it creates an in-group. But the people who know often learned from other people who also didn't have clinical training. That chain of informal knowledge is where things go wrong.